首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3275篇
  免费   248篇
  国内免费   8篇
耳鼻咽喉   30篇
儿科学   288篇
妇产科学   45篇
基础医学   519篇
口腔科学   21篇
临床医学   293篇
内科学   566篇
皮肤病学   37篇
神经病学   451篇
特种医学   96篇
外科学   471篇
综合类   62篇
预防医学   280篇
眼科学   47篇
药学   131篇
中国医学   1篇
肿瘤学   193篇
  2023年   25篇
  2022年   35篇
  2021年   91篇
  2020年   39篇
  2019年   67篇
  2018年   81篇
  2017年   54篇
  2016年   60篇
  2015年   71篇
  2014年   88篇
  2013年   106篇
  2012年   187篇
  2011年   200篇
  2010年   104篇
  2009年   85篇
  2008年   146篇
  2007年   141篇
  2006年   147篇
  2005年   137篇
  2004年   89篇
  2003年   115篇
  2002年   86篇
  2001年   61篇
  2000年   62篇
  1999年   71篇
  1998年   32篇
  1997年   27篇
  1996年   38篇
  1995年   33篇
  1994年   31篇
  1993年   33篇
  1992年   66篇
  1991年   57篇
  1990年   52篇
  1989年   71篇
  1988年   49篇
  1987年   59篇
  1986年   61篇
  1985年   52篇
  1984年   41篇
  1983年   46篇
  1982年   35篇
  1981年   28篇
  1979年   34篇
  1978年   30篇
  1975年   28篇
  1973年   26篇
  1972年   36篇
  1971年   27篇
  1970年   23篇
排序方式: 共有3531条查询结果,搜索用时 15 毫秒
61.
62.
63.

Objective

To evaluate the cost-effectiveness of financial incentives for human immunodeficiency virus (HIV) viral suppression compared to standard of care.

Study Design

Mathematical model of 2-year intervention offering financial incentives ($70 quarterly) for viral suppression (<400 copies/ml3) based on the HPTN 065 clinical trial with HIV patients in the Bronx, NY and Washington, D.C.

Methods

A disease progression model with HIV transmission risk equations was developed following guidelines from the Second Panel on Cost-Effectiveness in Health and Medicine. We used health care sector and societal perspectives, 3% discount rate, and lifetime horizon. Data sources included trial data (baseline N = 16,208 patients), CDC HIV Surveillance data, and published literature. Outcomes were costs (2017 USD), quality-adjusted life years (QALYs), HIV infections prevented, and incremental cost-effectiveness ratio (ICER).

Results

Financial incentives for viral suppression were estimated to be cost-saving from a societal perspective and cost-effective ($49,877/QALY) from a health care sector perspective. Compared to the standard of care, financial incentives gain 0.06 QALYs and lower discounted lifetime costs by $4210 per patient. The model estimates that incentivized patients transmit 9% fewer infections than the standard-of-care patients. In the sensitivity analysis, ICER 95% credible intervals ranged from cost-saving to $501,610/QALY with 72% of simulations being cost-effective using a $150,000/QALY threshold. Modeling results are limited by uncertainty in efficacy from the clinical trial.

Conclusions

Financial incentives, as used in HTPN 065, are estimated to improve quality and length of life, reduce HIV transmissions, and save money from a societal perspective. Financial incentives offer a promising option for enhancing the benefits of medication in the United States.  相似文献   
64.
65.
66.
67.
68.
69.
70.
We are accustomed to treating aging as a set of things that go wrong with the body. But for more than twenty years, there has been accumulating evidence that much of the process takes place under genetic control. We have seen that signaling chemistry can make dramatic differences in life span, and that single molecules can significantly affect longevity. We are frequently confronted with puzzling choices the body makes which benefit neither present health nor fertility nor long-term survival. If we permit ourselves a shift of reference frame and regard aging as a programmed biological function like growth and development, then these observations fall into place and make sense. This perspective suggests that aging proceeds under control of a master clock, or several redundant clocks. If this is so, we may learn to reset the clocks with biochemical interventions and make an old body behave like a young body, including repair of many of the modes of damage that we are accustomed to regard as independent symptoms of the senescent phenotype, and for which we have assumed that the body has no remedy.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号